Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Todays Updates


Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Marco Meglio


Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

How Social Robotics and Embodied AI Could Reshape Neurology Care Neal K. Shah


Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

Understanding the Therapeutic Potential and Promising Early-Stage Data on Azetukalner for Focal Onset Seizures Marco Meglio


Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

Special Report: Reframing Skin Pain in Atopic Dermatitis Mona Shahriari, MD, FAAD, Andrew Mastro, MS, PA-C


This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles


Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles

Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis


Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis

Older Patients on Maintenance Dialysis Underrepresented in RCTs


Older Patients on Maintenance Dialysis Underrepresented in RCTs

Todays Updates


Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Marco Meglio


Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

How Social Robotics and Embodied AI Could Reshape Neurology Care Neal K. Shah


Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

Understanding the Therapeutic Potential and Promising Early-Stage Data on Azetukalner for Focal Onset Seizures Marco Meglio


Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

Special Report: Reframing Skin Pain in Atopic Dermatitis Mona Shahriari, MD, FAAD, Andrew Mastro, MS, PA-C


This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles


Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles

Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis


Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis

Older Patients on Maintenance Dialysis Underrepresented in RCTs


Older Patients on Maintenance Dialysis Underrepresented in RCTs

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

BTK Inhibitor Active in Half of Patients With Richter Transformation

2.

Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.

3.

What is a "cancer vaccine" and is it the same as a COVID vaccine?

4.

No Cellphone, Brain Cancer Link; Testosterone Paradox; Breast Density and Cancer

5.

Research finds COVID-19 mRNA vaccine sparks immune response to fight cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot